Member Name: {{MEMFIRST}} {{MEMLAST}} DOB: {{MEMBERDOB}} PA Number: {{PANUMBER}}



## Juxtapid, Kynamro

## **Prior Authorization Request**

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155. If you have questions regarding the prior authorization, please contact CVS Caremark at 1-866-814-5506. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Pat Phy Spe Phy	ient's Name: {{MEMFIRST}} {{MEMLAST}}Date: {{TODAY}} ient's ID: {{MEMBERID}} Patient's Date of Birth: {{MEMBERDOB}} vsician's Name: {{PHYFIRST}} {{PHYLAST}} cialty:		
1.	What drug is being prescribed?  ☐ Juxtapid ☐ Kynamro ☐ Other		
2.	What is the documented diagnosis?  ☐ Homozygous familial hypercholesterolemia ☐ Other		
3.	What is the ICD-10 code?		
4.	Is the patient currently receiving Juxtapid? ☐ Yes ☐ No If No, skip to #7		
5.	Is the patient receiving Juxtapid through samples or a patient assistance program?  If Yes, skip to #7 □ Yes □ No		
6.	Has the patient achieved or maintained an LDL-C reduction greater than 20% from levels immediately prior to initiation of treatment with Juxtapid? ☐ Yes ☐ No		
7.	What is the patient's <u>untreated</u> (i.e., before treatment with any lipid-lowering therapy) LDL-C level? <i>ACTION REQUIRED: Attach supporting labs.</i> mg/dL □ Unknown		
8.	What is the patient's <u>treated</u> LDL-C level?  **ACTION REQUIRED: Attach supporting labs mg/dL □ Unknown		
9.	Does the patient possess mutations in both alleles at LDL receptor, ApoB, PCSK9 or LDL receptor adaptor protein gene locus? <i>ACTION REQUIRED: If Yes, attach chart note(s) and skip to #13</i> .    Yes   No   Unknown		
10.	Did the patient have either of the following? <i>ACTION REQUIRED: If Yes, attach chart note(s)</i> . □ Tendon or cutaneous xanthomas at age 10 or younger, <i>skip to #13</i> □ Evidence or diagnosis of familial hypercholesterolemia in both parents □ Neither − The patient does not meet any of the criteria listed above, <i>skip to #12</i>		

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Juxtapid, Kynamro SGM - 5/2020.

	uthorized Signature	Date (mm/dd/yy)
	information is accurate and true, and that docum available for review if requested by CVS Caremark	
	dromes, coronary or other arterial revascularization proced PTCA], coronary artery bypass graft [CABG] surgery])?	
15. Does the pati	ent have clinical atherosclerotic cardiovascular disease (	ASCVD) (e.g., myocardial infarction, acute
	ation of treatment with prescribed drug, is/was the patient a high-intensity statin, ezetimibe, and Repatha?	
	ent have known LDL-receptor negative mutations in both ther questions	h alleles?
a) Total of b) Tendo c) Prema disease/e revascula [CABG] d) Sudde e) Diagn familial emg/dL of sister, painfarction Total chot than 260	cholesterol at least 310 mg/dL m xanthoma  atture [i.e., before the age of 55 years (father) or 60 years are event (e.g., myocardial infarction, acute coronary syndron arization procedure [e.g., percutaneous coronary angiopla surgery])  an premature cardiac death before the age of 55 years (father) or 60 years (father) or	(mother)] atherosclerotic cardiovascular mes, coronary or other arterial asty [PTCA], coronary artery bypass graft ther) or 60 years (mother) the following: 1) An LDL-receptor mutation, ion; 2) Total cholesterol greater than (>) 290 ma in patient, first-degree relative (brother, e, aunt) or Family history of myocardial cond degree relative before the age of 50 or d degree relative or Total cholesterol greater
☐ Genetic co gain-of-funct ☐ No – The 1	patient's parents do not meet any of the criteria listed about of the patient's biological parents experienced at least or	familial defective apo B-100, or a PCSK9 ove ne of the following?
relative ☐ Famil degree re ☐ Total	on xanthoma in patient, first-degree relative (brother, sisted (grandparent, uncle, aunt) y history of myocardial infarction in a first degree relative elative before the age of 50 cholesterol greater than 290 mg/dl in an adult first or sec cholesterol greater than 260 mg/dl in a child, brother, or	we before the age of 60 or in a second
skip to #13. ☐ Total chole plus one	esterol greater than (>) 290 mg/dL or LDL-C greater that of the following:	n (>) 190 mg/dL
11. Does BOTH	patient's biological parents have a diagnosis of familial hollowing criteria sets? <i>ACTION REQUIRED: If Yes, in</i>	nypercholesterolemia (FH) confirmed by
Member Name:	{{MEMFIRST}} {{MEMLAST}} <b>DOB:</b> {{MEMBERD	OOB}} PA Number: {{PANUMBER}}